Becton, Dickinson and (NYSE:BDX) Releases FY23 Earnings Guidance
Becton, Dickinson and (NYSE:BDX) Releases FY23 Earnings Guidance
Becton, Dickinson and (NYSE:BDX – Get Rating) updated its FY23 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $12.07 to $12.32 for the period, compared to the consensus estimate of $11.97. Becton, Dickinson and also updated its FY 2023 guidance to $12.07-$12.32 EPS.
周四，Becton、Dickinson和(NYSE：BDX-GET Rating)更新了其23财年收益指引。该公司提供了12.07美元至12.32美元的每股收益指引，而市场普遍预期为11.97美元。该公司还将其2023财年每股收益指引更新为12.07-12.32美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several equities analysts recently commented on the stock. Morgan Stanley increased their price objective on shares of Becton, Dickinson and from $290.00 to $295.00 and gave the company an overweight rating in a research note on Friday. William Blair reaffirmed an outperform rating on shares of Becton, Dickinson and in a research note on Friday, November 11th. The Goldman Sachs Group dropped their price target on shares of Becton, Dickinson and from $319.00 to $272.00 and set a buy rating for the company in a research note on Wednesday, November 23rd. Evercore ISI dropped their price target on shares of Becton, Dickinson and to $270.00 in a research note on Wednesday, November 16th. Finally, Cowen dropped their price target on shares of Becton, Dickinson and to $255.00 in a research note on Wednesday, November 16th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $275.64.
几位股票分析师最近对该股发表了评论。摩根士丹利在周五的一份研究报告中将贝顿、迪金森和贝克汉姆的股票目标价从290.00美元上调至295.00美元，并给出了该公司的增持评级。威廉·布莱尔在11月11日星期五的一份研究报告中重申了对Becton，Dickinson和的股票的强于大盘的评级。11月23日，高盛夫妇在一份研究报告中将贝顿、狄金森的目标股价从319.00美元下调至272.00美元，并为该公司设定了买入评级。11月16日，Evercore ISI在一份研究报告中下调了他们对Becton，Dickinson股票的目标价至270.00美元。最后，考恩在11月16日星期三的一份研究报告中将他们对Becton，Dickinson的股票目标价下调至255.00美元。四名研究分析师对该股的评级为持有，五名分析师对该公司的评级为买入。根据MarketBeat的数据，该公司目前的平均评级为中等买入，共识目标价为275.64美元。
Becton, Dickinson and Stock Down 1.1 %
Becton，Dickinson和股价下跌1.1%
NYSE:BDX traded down $2.63 during trading hours on Friday, reaching $245.84. The company had a trading volume of 2,117,712 shares, compared to its average volume of 1,236,927. The company has a quick ratio of 0.63, a current ratio of 1.04 and a debt-to-equity ratio of 0.55. The firm has a market cap of $69.88 billion, a price-to-earnings ratio of 41.81, a P/E/G ratio of 2.23 and a beta of 0.54. The business's 50-day simple moving average is $251.52 and its two-hundred day simple moving average is $244.40. Becton, Dickinson and has a twelve month low of $215.90 and a twelve month high of $280.62.
纽约证券交易所：BDX在周五的交易时段下跌2.63美元，至245.84美元。该公司的成交量为2,117,712股，而其平均成交量为1,236,927股。该公司的速动比率为0.63，流动比率为1.04，债务权益比率为0.55。该公司市值为698.8亿美元，市盈率为41.81倍，市盈率为2.23倍，贝塔系数为0.54。该业务的50日简单移动均线切入位在251.52美元，200日简单移动均线切入位在244.40美元。贝顿，迪金森，并有12个月低点215.90美元和12个月高点280.62美元。
Becton, Dickinson and Announces Dividend
Becton，Dickinson和宣布分红
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date of this dividend is Thursday, March 9th. Becton, Dickinson and's dividend payout ratio (DPR) is 61.90%.
该公司最近还披露了季度股息，将于3月31日(星期五)支付。3月10日(星期五)登记在册的股东将获得0.91美元的股息。这意味着年化股息为3.64美元，股息收益率为1.48%。本次股息除息日期为3月9日(星期四)。Becton，Dickinson and的股息支付率(DPR)为61.90%。
Institutional Inflows and Outflows
机构资金流入和流出
A number of large investors have recently made changes to their positions in the company. Zions Bancorporation N.A. lifted its position in shares of Becton, Dickinson and by 13.0% during the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier's stock valued at $134,000 after purchasing an additional 58 shares in the last quarter. Evergreen Capital Management LLC raised its position in Becton, Dickinson and by 0.6% in the first quarter. Evergreen Capital Management LLC now owns 12,238 shares of the medical instruments supplier's stock worth $3,255,000 after acquiring an additional 67 shares during the period. Global Wealth Management Investment Advisory Inc. raised its position in Becton, Dickinson and by 3.1% in the first quarter. Global Wealth Management Investment Advisory Inc. now owns 2,313 shares of the medical instruments supplier's stock worth $615,000 after acquiring an additional 69 shares during the period. Brighton Jones LLC raised its position in Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier's stock worth $368,000 after acquiring an additional 112 shares during the period. Finally, Orion Portfolio Solutions LLC raised its position in Becton, Dickinson and by 10.7% in the first quarter. Orion Portfolio Solutions LLC now owns 1,181 shares of the medical instruments supplier's stock worth $314,000 after acquiring an additional 114 shares during the period. 87.08% of the stock is owned by institutional investors.
一些大型投资者最近对他们在该公司的头寸进行了调整。Zion Bancorporation N.A.在第一季度将其在Becton，Dickinson的股票头寸提高了13.0%。Zion Bancorporation N.A.在上个季度又购买了58股后，现在拥有这家医疗器械供应商504股股票，价值13.4万美元。Evergreen Capital Management LLC在第一季度将其在Becton，Dickinson的头寸提高了0.6%。Evergreen Capital Management LLC在此期间额外收购了67股，现在拥有这家医疗器械供应商12,238股股票，价值3,255,000美元。Global Wealth Management Investment Consulting Inc.在第一季度将其在Becton，Dickinson的持仓提高了3.1%。Global Wealth Management Investment Consulting Inc.现在持有这家医疗器械供应商的2,313股股票，价值61.5万美元，在此期间又购买了69股。Bright ton Jones LLC在第一季度将其在Becton，Dickinson的头寸提高了8.8%。Bright ton Jones LLC在此期间增持了112股，目前持有这家医疗器械供应商1,383股股票，价值36.8万美元。最后，Orion Portfolio Solutions LLC在第一季度将其在Becton，Dickinson的头寸提高了10.7%。Orion Portfolio Solutions LLC在此期间额外收购了114股，现在拥有这家医疗器械供应商价值314,000美元的股票1,181股。87.08%的股份由机构投资者持有。
Becton, Dickinson and Company Profile
贝顿、狄金森和公司简介
(Get Rating)
(获取评级)
Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.
Becton，Dickinson&Co从事医疗用品、设备、实验室设备和诊断产品的开发、制造和销售。它通过以下部门开展业务：BD医疗、BD生命科学和BD Intervative。BD医疗部门生产医疗技术和设备，用于帮助改善医疗保健服务。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免费获取StockNews.com关于Becton、Dickinson和(BDX)的研究报告
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet盈利节节攀升，增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
- 内部人士和机构收购金刚狼全球
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.
接受Becton Dickinson和Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Becton Dickinson和相关公司的最新新闻和分析师评级的每日简要摘要。